CRIS Cancer Foundation Impact Report 2020 **A TIME FOR RESEARCH** ## **UK Trustees** ## Letter from the Chair > Diego Megía Vice-president and co-founder > Marta Brime Secretary and Compliance > Nicola Amoroso > Eleonor Creaturo > Nuria Marti > Fernando Delgado > Alvaro Portanet > Snigdha Singh > Josefa Díaz Mercado ## > Lola Manterola > Ana de Paz > Ana Guilarte > Chavela Rodríguez > Marta Brime > Inés Martinez-Artola > Eleonor Creaturo > Kalie Murray > María Díaz > Rohini Tiwari > Lola Manterola Chair and co-founder _Cancer hasn’t stopped during “ the pandemic, but neither has the CRIS community. Thanks to the dedication and generosity of our supporters, we increased our annual investment in research by 15% in 2020._ CRIS stands for “Cancer Research Innovation in Science”. For 10 years, we’ve been investing in pioneering research into cancer. In that time, our objective has been to support scientists and clinicians to save lives. The Covid-19 pandemic has derailed the detection and treatment of cancer. Fewer referrals, disruption to treatment and the pausing of screening programmes mean many more people are tragically dying of cancer. Investing in science is an investment in all our futures. The pandemic has taught us that when we work together, positive progress is made. CRIS Cancer Foundation is an international community. We support the brightest research minds across Europe, who are working tirelessly on new treatments to help us survive and live longer. Research is the reason I’m alive today. I took part in a clinical trial for multiple myeloma which saved my life. Now it is a regular treatment, giving hope to cancer patients and allowing them to live their lives. We must invest in research so more adults and children with cancer get a second chance like me. Cancer hasn’t stopped during the pandemic, but neither has the CRIS community. Thanks to the dedication and generosity of our supporters, we increased our annual investment in research by 15% in 2020. This has allowed us to continue focusing on the areas of research that have fewer resources but immense potential. We’ve also been able to invest in scientists at a time when it’s been challenging for them to secure funding for their work. We added two new CRIS Units, invested in new research projects in pancreatic cancer and multiple myeloma and also supported young researchers through fellowships and grants. I’m incredibly proud that our charity responded with solidarity to the researchers and scientists during the pandemic. While maintaining our commitment to cancer research, we’ve funded several international Covid-19 trials. We’ve been able to fund three extraordinary projects to help reduce the devastating impact of the pandemic. These include using our knowledge to create novel treatments for cancer patients with Covid-19. Working together with Microsoft and Adaptive Biotechnologies, our researchers have shared their expertise to help tackle the virus. In 2021 we will invest in projects that create new cancer therapies which have the potential to reach patients sooner and improve their quality of life. We’ll also be introducing more grants and fellowships for scientists and researchers, so they have the stability they need to carry out their vital work. Thank you to everyone who has supported us in the last year. From our volunteers who keep our charity running, to our supporters whose generous donations allow us to invest in research projects worldwide. Cancer patients don’t have time to wait. Together we all have a part to play in supporting innovative cancer research. We need everyone to act now because peoples’ lives depend on it. ## _Lola Manterola_ CRIS Cancer Foundation Chair and Co-founder > Vani Krishnaswamy **----- Start of picture text -----**
About CRIS Cancer Foundation
**----- End of picture text -----**
## What we do We’re an international charity that funds research into pioneering new cancer treatments to give people the best chance of survival. Cancer is one of the leading causes of death in the world. Yet, many lives could be saved if scientists had the resources they need to carry out research into pioneering new treatments. We give scientists in the UK, Spain and France the support and funds to accelerate the discovery of cancer treatments for adults and children. By stepping in where there are gaps in funding and collaborating worldwide, we’re supporting research scientists to speed up innovative therapies – bringing hope to thousands of cancer patients. Over the last 10 years, we’ve given £18 million to research bodies such as the Institute of Cancer Research, so they can carry out vital research into cancer treatments. We’ve pledged to invest another £48 million over the next five years to save more lives. Our cancer facilities in public hospitals and other centres around the world are giving more patients the chance to access new treatments. Teams of doctors, researchers, nurses and immunologists work together in CRIS units to treat cancers such as brain tumours in children, ovarian cancer and prostate cancer. Our grants and fellowships give scientists the funding and support they need to carry out scientific research into cancer treatments. We’re determined that one day every type of cancer will have a treatment. By funding and supporting cancer research, we will save lives. ## Our mission To invest in cutting-edge research that provides treatments for people with cancer. ## Our vision A world where pioneering research gives every adult and child with cancer the best chance of survival. ## Our values - We are passionate and ambitious about making our vision a reality. - We make long-term commitments to scientists so they can carry out innovative research into cancer treatments. - We promote excellence in cancer research as we know this will lead to pioneering new treatments for people with cancer. - We collaborate with international institutions, research scientists, clinicians, people with a cancer diagnosis, volunteers and donors. - We inspire everybody to take action. We all have a role to play regardless of our background, experience or situation. ## Our highlights in 2020 ������������������������������������������������������������������������������� continued to support cancer research throughout 2020. Here are some of the ���������������������������������� ## **[Supporting efforts during the pandemic]**[. ] **1** With the support of our donors, we took part in several national and international Covid-19 vaccine trials. Scientists working on vaccines used the facilities at our CRIS units and drew on the experience and skills of our research scientists. We also funded a project that adapted a cell therapy used in childhood cancer treatments to treat patients with Covid-19. - **2[The opening of our new CRIS Unit.]**[ We opened ] the CRIS Cancer Foundation Biology Unit in the Institute for Cancer Research Centre for Drug Discovery in London, UK. This has brought scientists together to create new treatments and therapeutic approaches. **4[Researching childhood cancer.]**[ We ] supported a team at the Institute of Cancer Research, led by Professor Chris Jones, to publish a paper on improved treatments for babies with brain tumours. This is the largest and most comprehensive study of infant gliomas, a tumour that starts in the brain or spinal cord. We also continued to support projects focused on leukaemia in children and Ewing’s Sarcoma, a type of cancer that is common among young children. Research projects looking at child brain tumours were carried out in the Niño Jesús Hospital in Madrid and the Institute Gustave Rosy in Paris. The Hospital de la Paz in Madrid also continued to develop new personalised treatments for children without treatment options. - **3[Extended our partnership with the ICR. ]**[We ] supported the Institute of Cancer Research to carry out research into multiple myeloma, the second most diagnosed blood cancer. The pandemic halted laboratory activities for most of the year. Despite this, the Thoracic Oncology Immunotherapy Group was set up with four team members and started laboratory research. **5[Set up a new unit specialising in experimental ] therapies.** We opened a CRIS unit at the Hospital Clínico San Carlos in Madrid, to identify new cell therapies to treat ovarian cancer and breast cancer. - **7[Finding treatments for prostate cancer.]**[ We ] supported the Biomedical Research Institute of Malaga to continue researching treatments for prostate cancer. An Excellence Fellowship was also awarded to Dr. David Olmos, so he could continue researching treatments for tumours with a poor prognosis. In partnership with the Prostate Cancer Foundation, we awarded fellowships to two promising UK researchers: Dr Francesco Giganti and Dr. Anastasia Catherine Hepburn. - **6[Training researchers and awarding research ] fellowships.** Together with the Damon Runyon Foundation and the Prostate Cancer Foundation, we set up two new international scholarship programmes to support research scientists. This gives promising researchers the funding they need to increase their knowledge of cancer biology, so they can develop pioneering new treatments. In 2020, we also recruited new post-doc researchers through our Excellence and Talent CRIS Research Fellowship programmes. - **8[Developing treatments for aggressive ] tumours.** We funded several projects that developed treatments to tackle aggressive forms of cancer. This included a piece of work, led by Dr. Mariano Barbacid, which eliminated two key proteins in tumour development to reduce pancreatic tumours. **----- Start of picture text -----**
CRIS International CRIS ProjectsCo-Funding Grants With
International Institutions
Why we work worldwide CRIS Research Grants
We support scientists around the world to pioneer new cancer treatments. By working
together, we can accelerate scientific advances in cancer research. Sharing expertise
and knowledge globally will help people to live longer.
���������������������������������������������������������������������������
������������������������������������������������������������
Where we work
We work with state-of-the-art research centres and the
most reputable scientists to find new treatments for cancer. 11 14
Explore our map to find out where we’re supporting projects. 2619 27
25 1 10
18 20 21
What makes CRIS different? 3 22 28
23 13 24 15 8 2 6
> CRIS is international.dynamic charity, we are not restricted by As a small and 12 16 17 9 7 5 4
geography when selecting projects
to fund. We identify and support
excellence globally.
> Agile and flexible. We can respond
Cancer knows no boundaries
quickly wherever the need for support or
collaboration arises.
Cancer affects us all, regardless of age, �� ICR/Royal Marsden, London ��� ������������������������������������������
> Funding charitable activities. With socioeconomic status, gender, nationality �� ������������������������������������������� ��� �����������������������������������
small overheads, most of the money or geography. The disease is one of the �������������������������������������������������� ��� ����������������������������
we raise goes directly towards funding leading causes of death in the world, with ������������ ��� �����������������������
cancer research. one in six people dying of cancer. Yet, �� ������������������������������������� ��� �������������������������������
many of these deaths can be prevented.
> Funding research at every level. �� �������������������������� ��� �����������������������������������
To accelerate research, we fund all For 10 years, we’ve been working with the �� ����������������������������������������� ��� ���������������������������������
types of research projects – no matter international community to end cancer. �� ����������������������������������������������� ��� �������������������������������������
the experience of the researcher or the We’re currently funding research projects ������������������������������������������������� ��� Centre Hospitalier, Lyon
size of the project. This helps to make at the Institute of Cancer Research in ������������������� ��� �������������������������������������������
sure that every viable option to treat London and other research centres �� ���������������������������������� ��� ������������������������������������������
cancer is explored. across Europe, like the Biomedical �� ����������������������������������������������� ��� ��������������������������������������������
Research Institute of Malaga. This is �� ����������������������������������� ���������������
> Funding projects with fewer resources. helping scientists to make new medical ��� ICR/Royal Marsden, London ��� �������������������������������������������
We fund projects that have more discoveries that give cancer patients a ��� �������������������������������������� ��������������
difficulty getting funding, such as greater chance of survival. ��� ���������������������������������������� ��� ����������������������������������������������������
brain tumours in children.
��� �������������������������������������������� ��� �������������������������������������������
**----- End of picture text -----**
## CRIS International ## Why we work worldwide We support scientists around the world to pioneer new cancer treatments. By working together, we can accelerate scientific advances in cancer research. Sharing expertise and knowledge globally will help people to live longer. ��������������������������������������������������������������������������� ������������������������������������������������������������ ## Where we work We work with state-of-the-art research centres and the most reputable scientists to find new treatments for cancer. Explore our map to find out where we’re supporting projects. ## - **���** ������������������������������������������� ���������������������������������� ## The difference we have made to cancer patients ������������������������������������������������������������������������������ ���������������������������������������������������������������� **----- Start of picture text -----**
CRIS investment (£)
CRIS MULTI-DISCIPLINARY UNITS ADULT CANCERS
CRIS Immuno-oncology Unit 862,257 Pancreatic cancer 579,594
CRIS Translational Research Unit in Haematology 3,490,628 Breast and Ovarian cancer 722,100
CRIS Prostate Cancer Unit 892,097 Thoracic Immuno-oncology Group 704,000
CRIS Unit New Experimental Therapies 435,000 Multiple Myeloma 186,165
CRIS Childhood Cancer Unit 3,685,276 Bowel cancer 244,817
ICR Biology Unit 150,000 Imaging in Immunotherapy 96,917
PAEDIATRIC RESEARCH PROJECTS Cell Therapies in Blood Cancers 217,934
Childhood Brain Tumours (UK) 470,750 OTHER INVESTMENTS
Childhood Brain Tumours (France) 95,700 Support for Clinical Trials 3,699,785
Childhood Brain Tumours (Spain) 219,281 International Fellowships, Scholarships and
1,037,045
Ewing sarcoma in children 274,050 Grants to researchers
MLL leukaemia 153,338 Educational Projects and Scientific Dissemination 346,403
Pain Guide in Children with Cancer 47,589 COVID and cancer 117,129
TOTAL £18,727,855
**----- End of picture text -----**
## Research topics ## **53** **----- Start of picture text -----**
304
clinical trials
**----- End of picture text -----**
## lines of research funded including immunotherapy, myeloma, brain tumours and experimental therapies. were carried out across Europe because of the investment we made in cancer research. Scientists are using the research ���������������������������������� for people living with cancer. Adults and children with cancer were given new treatments through these trials. ## Clinical trials **----- Start of picture text -----**
£
£18
**----- End of picture text -----**
**----- Start of picture text -----**
����������������
**----- End of picture text -----**
**----- Start of picture text -----**
53
**----- End of picture text -----**
- ������������������ ������ **----- Start of picture text -----**
114
**----- End of picture text -----**
- ���������������� - ������������ ������� **----- Start of picture text -----**
11
**----- End of picture text -----**
- ������������ - �������������� **----- Start of picture text -----**
304 28
���������������
**----- End of picture text -----**
�������������������� ���������������� **----- Start of picture text -----**
502
**----- End of picture text -----**
**----- Start of picture text -----**
������������
**----- End of picture text -----**
**----- Start of picture text -----**
cancer foundation
**----- End of picture text -----**
**10 years** **24** ���� - ���������� **----- Start of picture text -----**
95 X3
**----- End of picture text -----**
- ���������������� ������������������ related ������������������������� - ���������������� ������������� - ���������������� **----- Start of picture text -----**
CRIS Partners
**----- End of picture text -----**
**----- Start of picture text -----**
cancer f o undation
JOIN THE CRIS COMMUNITY
���������������������������������������������������������������
��������������������������������������������������������������������
������������������������������������������������������������������
���������������������������������������������������������������������
��������������������
������������������������������
�������������������
������������������������������
���������������������������������������������������������������
��������������������������������������������������������������������
**----- End of picture text -----**
COIn￿lly Registration Number: 7493363 CRIS CANCER FOUNDATION A COMPANY LIMrrED BY GUARANTEE (CHARITY No. 1140193) REPORT AND FINANCIAL sfATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 Hackeryoung charter￿ Accountsnts CRIS CANCER FOUNDATION A COMPANY LIMITED B Y GUARANTEE (CHARITY NO. 1140193) ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 Index Page Report of the trustees Report of the auditors 8-10 Statement of fiTianrial activitie5 Balance sheet 12 Cash flow ststemeni 13 Notes fortning part of the financial statements 14-22 CRIS CANCER FOUNDATION REPORT OF THE TRUSTEES FOR THE YEAR ENDED31 DECEMBER 2020 The trnstees. who are also directors of the charitsble company for the purposes of c()rnpany law, present their report along with th¢ financial Statements for the year ended 31 December 2020. The financial ststements comply with the Charities Act 2011. the Companies Act 2006, the Memorandum and Articles of Association. and A¢counling and Reporting by Charities.. Statement of Recommended Practice applicable to charitlC5 preparing their accounts in accordance with the Financial Reportii)g Standard in the UK and Republic of Irrland (FRS 102) (effective l January 2015). ObJective5 actiYitSe5 The objects of CRJS Cancer Foundation {CRIS) are to protrct and promotr the health of the public through supporting research into the naiure, causes, diagnosis. prevenlion. treatrnent and cure of all forms of ¢anc¢r. including the development of research finding5 into prdctical applications for the pr¢v¢ntion, treatment and cure of cancer and to provide information and Tai5e public understanding of such m&tter5. Publie benetit The dire¢tOTS have complied with section 17(5) of the 2011 Charities ACL having due tegard for the Charity Cotnmi5sion's guidance on public benefit wh¢n Tevi¢wing th¢ trust's aims and objectives. Achievernents and performan¢e The Covid-19 outbreak has had a devastating financial impaci on UK charities. Esti¥nates from the National Council of Voluntary Organisations suggest charities lost at least £4.3 billion in income in the first l? weeks of the pandemic alone. A recent article in the Times shows that medical research charities such as CRIS have lost more than 400A of fijndraising income during the tTrandeTnie. The imwdct has had a huge impact on what we do and how we do it. CRIS has had to adapt and make change5 accordingly. Cancer hasn't stopped during the pandemic, but neither has the CRIS community. This has allowed us to continue focusing on the areas of research that have fewer resourecs but irnmen5e poienlial. We've also been able to invest in scieniists ai a time when it's been challenging for tl)em 10 secure fvnding for their work. We are incredibly proud that our charity responded with solidarity to the researchers and scientists working to find treatments and Yaccines for Covid-19. While maintainin8 our commitment to cancer research, we've been able to fund three extraordinary projects to help reduce the deva5ting impact of tlie pandeinic. These include adapting a cell therapy used in Childhood cancer treatments to treat patients with Covid-19. Working together with Micr050ft and Adaptive Biote¢hnologi¢s. our resca￿her5 have shared their expert15e to help tackle the virns. As 2 result of the many ehange in the Way we work. we were unable to org8nise any corporate or community fi)ndraising aciivilies as planned. In*erson fundraising events were also cancelled. We started 2020 with the success of our very first Christmas campaign. CRIS patron Garrett Curran trekked 115 km to the South Pole to raise money to fvnd research into paediatric braEn tumours. Garrett was part of an I l-stron8 team led by polar explorer Alan Chaniers MBE. Garret¥natcheddonations made by individuals. These were also matched by donations from companies. So, each individual donation was tripled. raising over an incredible £80.i I l in the UK as well as a significant amouni in Spain. We salute Garrett for his bravery and commitment to help children with cancer and their families. The 2.6 Challenge was a simple and way for everyone to do their bit to help charities during the Covid- 19 crisis. Virgin Money set up the challenge after the London Marathon one of the biggest fijndraising events in the calendar was cancelled. Fundraisers were asked to complete an aaivity based on th¢ numbers 26 or 2.6. The aim was to do this on or around Sunday 26 April, what would've been the date of the London Marathon. Our incredible supporters raised £16.450 for CRIS by taking on a variety of challenges. CRIS CANCER FOUNDATION REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2020 Each year. our main source of income is usually our Annual Fundraising Ball. But with social distancing guidelines in place, a ball with 400 guests in one venue wa5 itnp05sibl¢. So. in 2020. w¢ d￿ld¢d to bring the ball to our guests, using a virtual eveni platforni Wc wcrc absolutcly thrillcd to rai5c ovcr £740.000 on thc night. Thanks lo the gcncrosity of our spon50r R.J. O'Brien. all this money will go towards funding research into cancer treatments. As a result of thc abov¢ a¢tions, the total incom¢ from 2020 was at a fairly similar Icvel as 2019. Thcrc was DO significant loss in income despite the focus on fewer acuvities. This is ¢viden¢¢ of improvement in our strategies and the delivery of our activities as well as the credibility we have with our supporters and ¢ontacts. Nei income was however higher be¢ause of r¢duc¢d costs in fundraistng activities due to the Gala ditu)er being held virtually. Our effotts in communications and brdnding has resulted in an increased social media presence across platforn￿.. W¢bpag¢, Fac¢book, Twittcr and In5tagrdm. Our ¢Kl¢rnal communications with CRIS supporters has aLlowed the charity io succeed despite challenging circutLstances. Funding CRIS Cancer Foundalion The ¢h2rity has five principal sources of fi￿dIng.. Annual Ball The 9th Annual Bau hosted by CRIS OD the 13th of November 2020 as a virtual event was a treinendous success. The theme for the evening was. A Time For Research" which highlighted the need to support rcscarch into canccrtrcatm¢nts during thc paDd¢mic aDd b¢yond. Guests took part in a silent auctlOD and prize draw. Our supporters donated incredible prizes like a stsy at an exclusive holiday home and valuabl¢ art and sports memorabilia. Guests in London also enjoyed a delicious three-course dinner delivered to tbeir door. which was prepared by London restaurdnts Hispania and Pizatro. It was our first virtual event. and we were overwhelmed by the support wc rcCciV￿ from the CRIS ¢ott]munity, in¢luding loyal supporters, researchers, doctors and volunteers. We were absolutely thrilled to raise over £740,000 on the night. Thatths lo the generosity of our sponsor R.J. O'Brien, all this money will go towards funding r¢S￿Ch into can¢¢r tr￿tItI¢ll1$. Fund5 were raised through tickel Sales. a sil¢nt ￿ctiOn (£319.138) aod genero￿$ pledges (over £340.000)- The total rais¢d was over £770,000. This includes R.J. O'Brien's s]x)nsorship donation of over £30.000. With costs just over £28,000, this left CRIS with a nel gala income of £ 740,1)00, not significantly diffcrcnt fTOrn the £787,000 nei income from the 2019 ball. CRIS CANCER FOUNDATION REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2020 Fundraising aclivilies (non-corporate) As mentioned above, CRIS couldn't organise the established community fundraising campeigns such as MY SUPERCRIS CHALLENGE. including th¢ Royat Parks Half Marathon, the Beet Canccr challcngc and the Colour Run. Instead. we had th¢ 2.6 Chall¢ng¢ which rais￿ £16,450. Fundraising aclivities (corporale) As per reasons given above. we did not focus on cotp)rate fundrdising in 2020. We raised £18,600 from Corporates in 2020. As w¢ mentioned earlier, R.J. OBrien's Spo￿$0TCd the Annual Ball with a donation of £30,000. Single donalions Funds rdised from one-off and regular th)nations reached £83,707. GiftAid The total Gift Aid to be claimed from HMRC in 2020 was £63.078 FUNDING CANCER RESEARCH PROJECTS CRIS Cancer Foundation continues to sponsor cutttng edge research projects through a parthership with the Institutc of Can¢cr R¢s¢ar¢h {ICR) in the UK. In 2020, CRIS donated £451,000 to charitable activities. This included: l. Th¢ knllnunotherapy Project at the Institute of Can¢¢r R￿COrCh {ICR) in the United Kingdom. including the group coordinated by Dr. Asiero Klampatsa ((£309.000). Cancer Iminunotherapy, involving treatments that harness the body's own immune systcm to destroy tumours, is currently on¢ of the most exciting areas of dramatic progress in ¢ancer research and treatment. The total funding commitsnent amounts to £1.367271 pay&ble ov¢r 5 yeaTS. 2020 wa5 the second year of payment. 2. Childhood brain cancer project at the Institute of Cancer Research (ICR) in the United Kingdom, coordinaled by Piof. Chtis Jones (£54.753). CRIS'S support of thc Children's Brain Tumour Project started in November 2015 when CRIS entered into a Deed of Gift with the ICR, which approvcd a total payment of £138,500. A further donation of £94,250 was approved in 2017 and 2018. CRIS'S donation for thi5 proj¢cl in 2017-18 amounted to £94,250. As a result of thc outcomes of the projecL the board of tnjstees has agreed to enlcrcd into a n¢w Deed of Gift of 3 years for a total of £326,026. 3. With approval from the Board, we increased o¥Jr partnership with the ICR to fund a Multiple Myeloma project led by Dr. Charlotte Pawlyn. A payment of £40,165 was made in 2020. CRIS CANCER FOUNDATION REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2020 In addition. othcr charitable actlVLtiC5 in 2020 included= The MLL Leukaemia Project at the Hospital Sant Joan de Deu de Barcelong. coordinated by Dr. Mireia Camos (£15.000). This projec( is supported by a restrictrd donation. 2. Support for CRIS can￿ Foundation France office. A P￿ent of £28,550 was made a5 part of their share of the income from the fimdrdising gala. 3. A sum of £3,350 was made to the CRIS Can¢er Spain office for certain c05ts. revlew The results for lh¢ period ar¢ a5 S¢t oul on page I l and show thai the charity achieved a very successful nd raising period in 2020. Tor21 income for the yegr ended 31 Deceniber 2020 amounted to £1,040,75i (2019-. £1,062,721), of which £911,166 (2019.. £963,856) was rdised frotn events. After fimd raising costs of £93,011 (2019.. £159,542), the net fimd5 raised (excluding bank interest) for the P¢Tiod were £945,586 (2019: £901.030). Together with res¢rv¢5 brought forward of £840,544 {2019.. £719,790) 2nd bank interesi income of £2,150 {2019.. £2,149). the total available fijnds to meet the Charity's objectives in the period amounted to £1.788286 (2019.. £1.622.969). During ihe period CRIS made totsl donations of £450.898 (2019.. £723,346). The donations to the Institute of Caneer Research (ICR). which were made under deeds of 8iti amounted to £418.998 (2019.. £718.3461. At the financial period end. the cotal funds. all of which are unrestricred. available for caTry forward amounted to £1.297310 (2019.. £840,544). InvestmeTht policy and performance There are no re5triction5 on the charity's powcr to inv&8t and the current FM)licy is to invest short temi deposits with the charity's bankeTS. Reserves policy and going Concern The charity's policy is lo maintain a sutTicien¢ level of reserves to etrdble the opera(ing activities of the ¢harity to continue. With the exception of annual Bovernance costs. which are estima(ed at £7.500. the aTnount of fijnds required to operate the chariry is noi si8nificani a( an estimated amount of £78,000 per annum. Tiie t￿Stee5 do not charge the charity for the 5eTvice5 they provide and the events that are held are invariably self-fi]nding events. CRIS i5 accordingly in an enviable position as the risk of it not being able to operdte a5 a going concern due lo lack of fi￿&% is considered to be remot Strueture, governance and management CRIS Cancer Foundation {CRIS) was incorporated on 14 January 2011 as a ch8ritable company which is limited by guardntee with no share capitsl 3nd governed by its Article5 of As50cia¢ion. CRIS was registered as a charity with the Charity Commi55ion for England and Wales on 2 February 201 l. The liability of each member in d)e event of winding up is limiied to a maxijmurn of £1. In a¢oordan¢e with the governing documcnL there shall be noi less than three direcrors at any one time. The direetors, who are also the charity inLsiees. are nomially elecied by the members of the cotrpany in a general meeting. Tn]5tees are appointed on the basis of Specific skills and knowledge to enable them to make a contribution to th¢ management of the chartty. In order for trustees to undertake such responsibilitie5. appropriate Charity Commission publications. in particular the booklet 'The Essenttal Tn￿teeS.. What you need to know. is given to each iDJstee as part of their induction process. CRIS CANCER FOUNDATION REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2020 Risk management The trustees have reviewed the major and financial risks that Impact on thc work of thc charity and undertake reviews of risk management on a continuing basis. The systems that have been established enable the tNstees to r¢vi¢w and take n¢cessary steps to lessen these Tisks. COVID-19 COVID-19 has had a significant impact the ch8rities activities and illcome. Fundraising events have b¢en Cancelled but new straiegtes and budgets have been put in place and are constantly cvolviDg based on changing circumstances. The staff arc now working off-51te and online with the office premises now being partially used. The newly appointed full-time Fundraising Assistant and Administrator is now working reduced hours. Despite thc Current challenging environmcnt for fundraising and significant reduction in incomc. CRIS is Comtnitted to fulfilling all fuDding commitments to research projects in full. CRIS CANCER FOUNDATION REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2020 Reftrenee and administrattve KBformation Directors Maria DoloTes Manterola (aka Lola Mantertsla)- Chairnian Nicola Louise Amoroso Marta Brime Fernando Delgado Eleonora Geraldine Creaturo Nuria Marti Diego Megia Alvaro Portanet Snigdha Singh Josefa Diaz Mercado Treasurer Ana Dc Paz Comp*ny number 749336i Registered eharity number 140193 Registered office Quadrant House - Floor 6. 4 Thomas More Square, London Elw IYW AudTtors UHY Hacker Young, Quadrant House, 4 Thomas More Square, London Elw IYW BankeTS Clydesdale Bank. 88 Wood StreeL LoT]don EC2V 7QQ Solltitors Bate5 Wells & Braithwaite London LLP 24 Cannon Stree( London EC4M 6YH CRIS CANCER FOUNDATIOTrI REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2020 Responsibilities of the Board The Trustees who are also th¢ directors of th¢ Foundation for th¢ purposes of company law are responsible for prcparing the Tru5tees' Report and the financial ststements in accordance with applicable law and United Kingdom A¢counting Staudards {Uni*d Kingdom Generally Accepted Accounting Prdctice). Company law requir¢s th¢ Trust¢¢5 to pr¢par¢ financial statemcnts for each financial year which give a true and fair view of the slate of affairs of the Foundaiion and the In￿Ming resources and application of resources, including the income and expenditure, of the Foundation for that period. In preparing these finaJJcial ststements, the Trustees are required to: s¢l¢ct suitabl¢ accounting policics and then apply them consistentIy' observe the methods and principles in the Charities SORP- make judgements and estimates that are r￿onable and prudenl state whether applicable UK Accounting Stsndards have been followed. subject to Any material departures di5c105ed and explain¢d in th¢ acxounts" and prepare the financial statements on the going concern b&sis unless it is inappropriate to presume that th¢ Foundation will continue in business. The Trustees responsible for keeping proper accounting records that disclose with r¢asonabl¢ a¢¢uracy at any tiin¢ th¢ finan¢ial position of th¢ Foundation and cnablc the Tru51ees to ensure that the financial ststements comply with the Companies Act 2006. The Trustees are also responsible for safeguarding the 485ets of the Foundation and hence for taking reasonable 5tep5 for the prevention and detection of fraud and other irre8ulariti¢s. This report has been prepared in accordance with the special provisions relating to small companies within Part 15 of th¢ Companie5 Act 2006. By order of the Board.. l*ifiki Bi'i]Dè- Director Dat¢: 21 July 2021 UHY Hacker Young LLP Quadrant House 4 Thomas More Square London E1W 1YW Hackeryoung charter￿ Accountants INDEPENDEPIT AUDITORS, REPORT TO THE MEMBERS AND TRUSTEES OF CRIS CANCER FOUNDATtON FOR THE YEAR ENDED 31 DECEMBER 2020 Opinion We have audited the financial stsiements of CRIS Cancer Foundarion (the 'Chariry') for the year ended 31 December 2020 whi¢h comprise the Statement of Financial Activities, the Balaiice Sliect, die Cash Flow Statement and thc notes to the financial ststemerbts. including significant accounling policies. The financial T¢POrting fraJncwork ihat has be¢n applied its thetr preparation És applicable law and United Kingdoni Accouiiling Standards, Lncludin8 Financial Reporting Standard 102 'The Financial Reporting Standard appli¢able in tlie UK and Rcpublic of Ircland (Unitrd Kingdom GeneTally Accepted A¢¢ouniing Pro¢tice)'. In our opinion tl)e financial statements.. giv¢ a tru¢ and fair view of the State of the Charity's affairs as at 31 Dccernbcr 2020 and of its net movement in fijnds, ineluding the income and expenditure. for thc PCTiod then etTrded: have been Propcrly prcparcd in accordarKe with United Kingdom Genenlty Ac¢¢pt¢d Accounting Practice., and have been prepared in accordancc with thc requircmcnts of the Companie5 Act 2006. Bx5i$ foT OPIIIIOII We ¢ondu¢ted our audit in ac¢ordanc¢ with In￿rnational Stsndard5 on Audiiing IUKI IISAS (UKII aiid applicable law. OUT responsibilities under those Sthndards are fvrther described in the Audiwr's responsibiliiie5 for ihe audii of the financial srotements %¢iion of our report. We are independent of the ChaTity in a¢¢ordanc¢ wilh the ethical requirements that are relevant to our audit of the finan¢ial statements in the UK, includin8 tlie FRC'5 Ethical Standard. and we have fvlfilled our otjier ethical responsibilities in accordaiice ivitli these requirements. We believe that the audit evidence have obtained is suffi¢i¢nt ood appropriate io provide a basis for our opinion. Conclusions relating to going con£crn In auditiiig the financial statements. wc have coD¢luded that th¢ tnLStees' L5e of the going concern ba515 of accounting in the preparaiioTh of the financial statements is approprtate. Based on the work we have perforned. we have noi identified any macerial un¢effainii¢5 relating io events or conditions that. individually or collectively. tnay wt significant doubi on the Chariry's ability to continue as a going concern for a period of at I￿st I? months frnm when the finathcial stsiements are audiorised for issue. Our responsibilities and the resporLsibilities of the tru5tces with [esp￿t to going concern are described in thc relevant s￿li0n5 of thi5 r¢porL Other informatio Tlie other iiifortnation cornpriscs the infomiation included in the Tn]stces' RewrL Our opinion on the financial Statements does not cover the other inforrnation and. except to the ¢￿¢￿1 oth¢rwkse explicitly Stated in OUT repor( we do rK)t exprcss any form of assurance ¢on¢lusÈon therei)n. In connection with our audit of the frnancial sta(emenrs. our r¢S￿nsIbIlity is to read the other informaiion and, in doing so. consider ivhether the oiher inforniatioii is materially incoiisisieni widi the fli1￿7¢idI slaiemeiits or our knowledge obtained in the audit or otherwis¢ appeats io be materially mi5Statcd. If we idei)tify such JD3tcrial iiiconsisiciicies or apparent material n)issiaien?enw we are required to d¢t¢Tmine i¥hethei there Is a material misstatement iii the fitjancial statements or a material mi5Stat¢mrni of th¢ other inforn?aiion. If. based on the work we have performed, wc conclude that ihcre is a material missts*m￿L of thi5 Other inforniation. we are required to report that fact. We have nothiThg lo r¢port in this regard. UHY Hacker Young LLP Quèdrant House 4 Thofflas More Square Lthdon E1W 11W Hackeryoung Chartered AccokJnt8nts INDEPENDENT AUDITORS, REPORT TO THE MEMBERS AND TRUSTEES OF CRIS CANCER FOUNDATION FOR THE YEAR ENDED 31 DECEMBER 2020 Matters on which we are required to report by exeeption In the light of the knowledge and understanding of the ChaTity a[￿ its environment obtained in the course of our audit, we have not identified material missiafrwents in the TTusiees' Repon (which in¢o¥pordtes the directors, report). We have nothing to report in respeci of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion-. adequate and Proper accouniing records have not been kepL or rewrns adequate for OUT audit have not been received from branches not V15lted by us; or the financial State￿entS ate not in agreement wtth the accounting records and returns; or certain disclosures of irusiees. iemunerarion specified by laiv are noi made. or we have noi received all the inforn)ation and explanations we require for our audit. the trust¢e5 W¢Te not ¢nlitled to prepare the financial statemEnts in aecordance with the small companies regime and lake advantage of the small Companies. exempiions in preparing the rrustees, rep)rt and from the requirement to prepaie a stsategic re￿rt. ReSPOD5ibilities of trustee5 As explained more fully in the Irustees. respK)nsibilities sthtement set out on page 7. the in]stces are rcspon5ible for the PTeparation of the financial statements which give a true and fair view. and for such intemal control as the trustee5 determine 15 necessary to enable the preparation of financial stateTnents that ale free from material misstat¢ment, whether due to fravd or ¢rroT. In preparing the financial statements. the tru5te&s are responsible for assessing the Charity's ability to cortiinue as a going concern, disclosing as applicable, matter5 related to going conccrn and using the going concern basi5 of accounting unless The trustees eiiher iniend io liquidaie ihe Charity or io cease operations. or have no rcalistic alt¢rnativ¢ but to do so. Auditor's responsibilities for the audit of the financial staternents Our objcetivo% are to obtain reLwnable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error. and io issue an audiiorfs report that in¢lydes our opinign. R¢asonable a55uranc¢ is a high l¢v¢l of assurance, but is not a guarantee that an audit conducied in accordance with JSAS (UK) wll always detect a material missratement when ir exists. Misstatements can arise from fraiid or error alld are considered material if, individually or in the ag8te8ate, they could ieasonably be expected to influence the economic decisions of users taken on the b&%is of these financial statements. Irregularities, Értcludirtg fraud, are instances of non-compliance with laws and r¢gulatiorLS. We design procedures in line with our responsibilitie5, Outlined above. to detect material misstatements in respect of irregularities, including ftaud. The ex￿nt to which our procedures are capable of detecting irregularitics, including fraud, is detailed below. Based on our understanding of rhe Chariry and the industy in which it operdi¢S, we identified that the prin¢ipo1 risks of Don-¢ompli8nce with laws and regulaiions rela(ed w the acts by ihe Chariry. which were contrary to applieable laws and regulaiions including fraud. and we considered the extcnr to which non compliance might have a maierial effect on the financial statements. We also considered those laws and regulations that have a direct irnpact on the prepataiion of the financial statewKnis such as the Compani¢s Act 2006. We evaluated management's inceniives and opportunities for fraudylcnt manipulation of the financial staiements (including the risk of oveJTide of controls), and determin¢d that the principal risks were related w inflated income. UHY Hacker Young LLP Qu8dr3nt House 4 Thoma5 b￿re Square Lon(JM E1W IYW Hackeryoung Chanered Accountants INDEPENDENT AUDITORS, REPORT TO THE MEMBERS AND TRUSTEES OF CRIS CANCER FOUNDATION FOR THE YEAR Ef4DED 31 DECEM& BER 2020 Audit proceduT¢S perfomed included.. review of rhe financial statettjent disclosures to underlying supporting documeniation, enquiries of management and testing of journa15 at]d evaluating whether there was evidence of bia5 by the Ttusiees that r¢prtsented a risk of rnaterial misstat¢m¢nt due to fraud. Th¢rc are inherent limitslions in ihe audit procedures described above and the fiwther remtsved non- Compliance with laws and regulations is from the events and ttansactions reflected in the financial statements. Ihe less likely we would become awere of IL A150, the tisk of not detecting a material misstatement due to fraud is higher than the Tisk of noi detecting one resulting from error. as fraud may involve d¢liberate concealment by, for example. forgery or intentional misrepresentsiions, or through collusion. A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at.. www.frc.org.uklaudiwrsr¢sponsibiliiies. This d&sciiption fom15 Part of our auditor's reporL Use of our report This report is made solely w the Charity's members, a body. ID occordance with Chapter 3 of Part 16 of the Compani¢5 Act 2006. Our audst work has been undettsken so that we mighi statc to the Charity'5 metnbeis ihose matters we are required to slate io rhem in an audirors, r¢port and for no other purpose. To the fullest cxtent pemiiiied by law, we do nor a¢cepr or a￿UMe responsibility io anyone other than the Charity and its menibets as a body, for our audit wo￿. for this report. or for the opinion5 w¢ have fornied. Raehel Chim (Stnlor Statutory Auditor) UHY Hacker Young Siaiutory Auditor Quadrant Hoiise 4 Thomas More Square Lx>ndon Elw IYW Date= 4 August 2021 10 CRIS CANCER FOUNDATIO1¥ STATEMENT OF FINANCIAL AcfIvITIES FOR THE YEAR ENDED 31 DECEMBER 2020 Unrestricted Restricted fund$ fund5 Total Unre5trict¢d Restricted fund5 funds funds 2020 Tot21 funds 2019 r40tss Incoming re50urtes Income from.. Donations and legaci&s 4)ther trading activitles -invesunenis 233.124 790,473 2.156 15.000 248.124 79).473 2.156 165,774 879.798 2.149 15.000 180.774 879.798 2,149 Total incoming resourc 1.025.753 15.0(M) 1.040.753 1.047.721 15.000 1,062,721 Expenditure on". Raising funds.. FutLdraÈsing events 93,011 93,011 159.542 159.542 Charitable a¢tÈvilics.' Donations made 475.976 15,O¢N) 490.976 767.425 15.000 782.425 Total 568.987 I5.(￿￿1 583.987 926.967 15.000 941.967 Nel movement in fun¢15 456.766 456.766 120.754 120.754 R¢conclllatlon of funds Total fund5 brought forward 840,544 840,544 719,790 719.790 Total fuNd5 ￿rrIed forward 1297,310 1297.310 840.544 840.544 Th¢ T¢sults for thr p¢ri¢)d dcrivcd from continuing opcrntions. There were no r¢cognised gains or 1055es. other than those passing through the ststement of financial activities. CRIS CANCER FOUNDATION BALANCE SHEET AS AT 31 DECEMBER 2020 31 De¢ember 2020 31 December 2019 Notes Ffixed assets Tangible assets 18,911 24,068 Current assets Debtors Cash at bank 116.278 1,171,830 117.684 720,367 1,288,108 838,051 Creditors: Amounts falling due Ivithln one year (9,709) (21.575) Net current assets 1,278,399 816.476 Total a55et5 le55 current liabilities 1,297.310 840,544 Net wets 1,297,310 840,544 Funds of the charity: Unrestricted funds Restricted funds 10 1297,310 840,544 1,297,310 840,544 Approved by the Board and authorised for i&sue on 21 July 2021 Id1rta Bri]ZLe- Dlréttor Company Iyumber: 7493363 12 CRIS CANCER Fouf4DATION CASH FLOW STATEMENT AS AT 31 DECELVIBER 2020 31 Dec 2020 31 De¢ 2019 Notes Operating & investing activities R¢¢¢ipis of interest Receipts of other cash Payment of charitabl¢ grants Payment of expenses Payment of tangible ass¢ts Depreciation charge of tangible a5S¢ts 2,156 1.030,359 (450,898) (135,312) 2,149 1,025,556 (823,721) (115,128) (25.788} 1.720 5,158 In¢r¢&se in casb from operating & investing activities (A) 451,463 64,788 Increase in cash (B) 451,463 64.788 (A) Recone511atlon ofchanges in resource5 to net ca$h inflow from operating & investing #etivities 2020 2019 Putlhase of tsngible assets Depreciation of tangible fixcd a55¢ts Net incoining resources (Incr¢2se)l Decrease in debtors Increasej (Dccrcasc) in ¢r¢ditors (25,788) 1,720 120.754 139,515) 7.617 5.158 456,765 ,406 (11,866) 451,463 64,788 (B) Analysis of ehanges An Cash balances during the year 2020 2019 Cash at beginning of period Cash at end of period 720,367 .171,830 655,579 720,367 Increase in cash 451,463 64,788 13 CRIS CANCER FOUNDATION NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 A¢counting policies Company iTrformgti0 Cris Cancer Foundation is a private company limitrd by guafdniee ineorpordted in England and Wales. The registered oifice is Quadrant Hous< Floor 6. 4 Thomas More Square. tA)ndon. El W iyw. Accounting convention These fltiantial 512tetnents have been prepared tn ac￿rd3￿Ce with Accounting and Reporting by Charities.. Siaternent of RccomTnended Prdctice appli¢abl¢ to ¢harities PTeparing their accounts in accordance with the Financial ReF>Orting Standard applicable in the UK and Republic of Ireland (Charities SORP FRS 102) (effective l January 2015), llie Financial R¢porting Standard applicable in the UK at]d Republic of Ireland" (FRS 102) at]d th¢ Charities A¢t 2011 and the requiTements of the Companies Aci 2006 as applicable lo companies subject to the small companies regime. The financial Statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £. CRIS Cancer Foundation meets the definition of a public entity under FRS 102. The financial 5tstements have been prepared on the historical cost convention and the principal accounting policies adopted are set out below. Fund5 Structure Restricted funds are funds which are to be used in accordance with specific restrictions imposed by tlie donor. Unrestricted fitnds are funds which are used in accordance widi the charitable objects wt tlie discretion of the trustees. Incorning resources Incoming resources are aCCn￿ and included in the SOFA when the charity is entitled to the incon)e. the receipt can be quantified and is probable and deferred when they relate to future accounting periods. Gift Aid receivable is included in income when there is a valid declararion from the donor and the donations has been received. The following policies apply io the following specific caiegories of income from fijndraising events.. Incomefi'om Annual Gala Dinner Ticket, auction and sponsorship income frorn ihe Annual Gala Dinner is disclosed under other trading activities and recognised when receivable. Incomefrom personal challenge andoiherfvndrai5Eng tveni$ Maraihon, bike Challenge and other ￿ndraisIng income. which are in substance donations. are disclosed &5 donations when reccivable. Investment income InVeSt￿ent inconie repre5cnted by interLst on rnijnies held on deposit is included in SOFA when receivable by the charity. 14 CRIS CANCER FOUNDATION NOTES TO THE FINANCIAL STA TEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 Aecounting policits (continued) Resources expended and irrecoverable VAT Liabilities are re¢ggni5ed as resources expended a5 soon as there is a legal or constructive obligaiion committing the charity to the expenditure. All expenditure is accounted for on an accrua15 b85is and has been ¢las5ified under headings that aggregate all costs related io the category. Irrecoverable VA T 15 charged against the category of resources expended for which it w&5 incurred. Going concer The accounts have been preparEd under the going concem basi5 &5 the trustee5 are of the opinion that the charity's forthcoming events, including the ar￿Ual Charity Gala Dinn¢r, plus some reserve funds will cover minimal operational costs and enable the charity io meet its objectives of fvndiT)g ¢an¢¢r research. Tangible fixed a$5ets Tangible fixed assets or¢ 51ated at cost (or deemed Cost) or valuation less accumulated depreciation and accurnulated impairnient Ios5¢s. Cost in¢lud¢s ￿$ts dirKt]y ¥ttributabl¢ to making the asset capable of operating a5 intended. Depreciation is provided on all tangible fixed a￿ets, at raies calculated to wrtte off the cosi, less estimated residual value. of each assec on a sysiematic basis over its expected useful life as follows: Fixwres and fittings 20¥• Oll CO FiDan¢ial instruments The cotnpany has eleC￿d to apply the provisions of SEclion I I 'Basic Financial In5trurnents' and Section 12 '0ther Financial Instruments Issues. of FRS 102 to all of its financial instruments. Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of ihe instrumenL Financial assets and liabilities are offtei. wilh the net amounts presented in the financial staieTnents. when there is a legally enforceable righi ts) 5cI off the retognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. Basie finantlal assets Basic financial 85sets, which include debtors and cash 8nd bank balances, are initially measured at transaction price including iransaction costs and are subsequently carried at amortised cost using the effective Enterest method Unle55 ihe aTrangernent ¢on5titutes a financing transaction. where th¢ transaction is measured at the present value of the future receipts discounted at a market rate of interesL Financial a55ets c[￿lfied receivablc within one year are not arnortised. 15 CRIS CANCER FOUNDATION NOTES TO THE FINANCIAL STATEMErfrs FOR THE YEAR ENDED 31 DECEMBER 2020 Accounting polieies (continued) Impairment of finaycial Assets Financial assets, other than those held at fair value through profit and 1055. are as5CSStd for indicaLoT5 of impaimient at each reporting end date. Financial wets are impaired Whe￿ there is obj¢¢tive ¢viden¢e thaL as a result of One or more events that occurred after the initial recognition of the financial asseL the e51irnated fijture cash tlows hav¢ been affected. If an asset 15 impaired, the irnpairment loss 15 the difference between the carying amount and the present value of the cstimated cash flows discounled at the asset's original ¢ffective inter&8t rate. The impaimieni loss is recognised in profit or Ioss. If there rs a decrease in the impairrnent loss arising from an event orxu￿lng 3fter the impairment was recognised. the impaimient is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amounl would hyve been. had the impairnient not previously been recognised. The impairment rever581 15 recogniscd profrt or Ioss. DerecognitiOD of financial assets Financial assets are derecognised only when the conlrac(ual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards tsf ownership to another entity. or if sorne significant risk5 and rewards of owneTship are retained but control of Ihe asset h8S trnn5f¢rr¢d to ¥noth¢r party thal is able to sell the asset in its entirety to an unrelated third party_ Classifit2tiQD of financi￿1 liabilitie5 Financial liabilitie5 and equily Ill5tTUtnents 8re cl8ssified according lo the substsnce of the ¢ontrdclual arrangements entered into. An equity insuument is any contract that evidences a residual interest in the assets of the company aftu deducting all of its liabilities. B85ic financial liabilities Basic financial Itabilities. including creditors, bank loan5. loans from fellow group ¢ompanies and preference shares that are classified as debt. are initially recognised at transaction price ullle5S the arrangement constitute5 a financing transa¢iion. where tlie debt instwinent is nieasured at the present valu¢ of the fvrure receipts discounted at ¥ rnarkei rate of interesL Financial liabilities tlassified as payable wiihin one year are no( amonised. D¢bt instruments are 5ub5¢quentty carried at amortised c05L Using the effcctive interest fdle rnethod. Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payabl¢ are cla55ified as ¢urr¢nt liabilities if payment 15 due within one year or Iw. If not. they are presented as non-current liabilitie5. Trade ¢rediior5 are recognised initially at transaction price and subsequentty measured at amorti5ed cost Using the effeciive interest method. Derecognition or rinanci#l liabilitie5 Financial liabilitie5 are derecognised when the ￿MpanY'S contracthal obligation5 expire or ar¢ dis¢harged or ¢8n¢¢ll¢d. Operating leAses Rentals payable under operaiing leases, including any lease incentives received. are charged to income on a straighi line basis over the tern) of the relevant lease. 16 CRIS CANCER FOUNDATION NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER2020 Employees There was on average 2 employees in the period (2019: 2). Analysis of staff eosts 2020 2019 Salaries and Wages SoeiaS Security Costs Pensions 50.885 1,175 1.129 64,298 1.333 53,189 68,260 Hlgher px5d staff The number of employees whose employee benefits (excluding employer pension costs) exeeeded £60.000 wa5 0. (2019 -. 0) Incomt and tTrdowments 2020 Total 2019 Total Unrestricted R¢stri¢ted 3.1 Donation5 and legaeies Direct gifts from individua15 and organisation5 Events and other income 12,431 120.693 15,000 127,431 120.693 96.716 84.058 233,124 15,000 248,124 180,774 3.2 Other trading attivitie5 Annual Gala Dinner 790.473 790.473 879,798 790.473 790.473 879.798 3.3 Investments Bank interest 2,156 2.156 2,149 17 oorA C$0tsTr4mP- oor￿￿￿￿ 00 V) 4n L¥J￿￿￿4￿ 4Dr 00￿￿400 OOthtr-*p4 00thr4￿r oor40•- CRIS CANCER FOUNDATION NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 Tangible r￿ed assets Fixtsre5 Total Fittings Cost or valuation: At l January 2020 Additions 25,788 25.788 At 31 December 2020 25,788 Depreciation: At l January 2020 Charge for the year At 31 December 2020 ,720 5,157 6,877 1,720 5.158 6,878 N¢¢ book vaLue'. At 31 December 2020 18,910 18,910 At 31 December 2019 24,068 24,068 Debtors: amounts falling due with one year". 31 Dec 2020 31 Dec 2019 Trade DebtOTS Prepayments Other debtors 104,078 7.700 4,500 108,213 4.971 4,500 116,278 117,684 Other creditors: amounts falling due within one year 31 Dec 2020 31 Dee 2019 Other crcditor5 and accrua15 9.709 21,575 Deferred IDwme 31 Dee 2020 31 Dec 2019 Deferred incoine is included within.. Crcditor5 due within one year 21.575 Deferred income at l January 2020 Relca5cd frotn previous years Resources deferred in the year 12.373 (12,373) 12,373 12.373 20 CRIS CANCER FOUNDATION NOTES TO THE FINANCIAL ￿ATEl￿ET+rrS FOR THE YEAR ENDED 31 DECEMBER 2020 FI￿ancIal instruments 31 Dec 2020 31 Dec 2019 Carrying amount of financial ￿ets. Debtors Cash at bank 104,078 1,171.830 108.213 720.367 1,275,908 828,580 Carrying amount of financial liabilities= Other creditors 1,275,908 828.580 10 Operating lease commitments At the reporting end date, the charity had outstandivtg commitsnents for fulure minimum lease payments under non-cancellable operating leases, which fall due &$ follows.. 31 Dee 2020 31 Dec 2019 Within l year 2-5years 18,900 54.000 21,600 75.600 72,900 97,200 11 Analysis of¢b*rit#bl¢ fuDds B%lanc¢ 1¢ 31 Dec2019 In¢omillg resources Resourc￿ Balance at eXpe￿ded 31 Dec 2020 Unrestricted funds". Generdl fuTMts 840.544 1,025.753 (568.987) 1297.310 840.544 1,025.753 (568.987) 1,297.310 Restricted funds 15.(KXJ (15.000) Total 1,040.753 (583.987) ,297,310 21 CRIS CANCER FOUNDATION NOTES TO THE FINANI CIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 12 Analysis of ttet assets behveen funds Ullrostrieted funds Re5trictwJ funds Total 31 Dee 2020 Total 31 Dcc 2019 Fixed assets Debtors Bat Creditors 18.911 116.278 1.171,830 (9.709) 18.911 116,287 .171.830 (9,709) 24,068 117,684 720,367 121.575) .297,310 1,297,310 840.544 13 Trustees, ejnoluments No irustee or any person connected with a trnstee has received or is due to receive any remuncration or ¢Kpens¢s for lh¢ pcri(MJ directly or indirectly from rhe charity's funds. 14 Related party trans*etiOllS CRIS made donations of £3.350 (2019= £Nil} io Fundacion CRIS d¢ Investigacion pard V¢ncci' el Cancer, a charitable organisation regi51crcd in Spain and related io CRIS by virtue of common ttust¢¢s, Lola Manterola and Diego Megia. CRIS a150 made a donation of £28,550 (2019.. £5,000) to CRIS Can¢¢r France. a charitable organisation which wa5 ncwly registered in Paris, France and related to CRIS by virtue of common tNstees, Lola Mantemla and Diego Megia. During th¢ period, the Irustee5 made donations to CRIS totalling £184.097 (2019.. £119,730). 15 Tax4tion As a Charity, thc Foundation is exempt from UK corporalion tax to the extent thai its in¢oine is applicd to lis charitable objects. No liability arose in the year. io Cupital commitments At the year end. the charity is Committed to make dollation of £776.189 (2019.. £1.140,022) to ICR projects through deeds of gifts. 22